Pakistan ke Drug Regulatory Authority of Pakistan ((DRAP) ne 19 February 2024 ko 146 medicines ki prices mein increment ki announcement ki hai, jo National Essential Medicine Lists (NEML) mein shamil hain aur jo mushkilat ke maqam par hain.
Ye izafa pichle mahine ke notification ke mutabiq aaya, jab medicine ke companies ne unki financial viability aur market mein kami ki wajah se in medicine ki manufacturing se inkar kar diya tha.
HARDSHIP CASES?
Drug Policy 2018 ke mutabiq, medicine ke mushkilat maqam woh maqamat hote hain jahan kisi medicine ke manufacturer ya importer apne kharchon ko cover nahi kar sakta aur munafa hasil nahi kar sakta, jo policy ke mutabiq set formula ke mutabiq hota hai. Drug Policy 2018 ke mutabiq, har teen saalon ke baad hardship cases me qeemat barhane ki ijaazat hoti hai.
LAST TIME PRICES HIKE
Last time hardship cases me medicines ki prices ko October 2020 mein barhaya gaya tha jis mein 94life saving drugs shamil thin. Halankey, is baar sirf 146 medicines ki qeemat barhai gayi hai jo zaroori medicines ki fehrist mein shamil thi.
Baqi medicines ki qeemat ko companies khud barha sakti hain Government ki taraf se regulated ho jane ke baad. Medicines jo zaroori medicines ki list mein zyada hain unko faida hoga – ya phir un medicines ke maamlaat mein jo mushkilat ka zyada samna karte hain. Ye potentially SEARL aur GLAXO jaise companies ko bhi shaamil kar sakti hain.
PRICE HIKE OF LIFE-SAVING MEDICINES
Medicines jin me price increase hue un me llife-saving drugs, injectables and oral antibiotics, drugs to treat inflammation, psychiatric conditions, autoimmune diseases, cancer, cardiovascular diseases including hypertension, fungal illness, allergies, diabetes, synthetic hormones for female health conditions etc. shaamil hain.
List mein MMR aur typhoid jaisi bimariyon ke vaccines, nebulizing solutions, eveloped diseases ke liye iodinated contrast agents aur anesthesia drugs bhi shamil hain.
ANTICIPATING BROAD-BASED SECTOR PROFITABILITY IMPROVEMENT.
Price hiked drugs me Government ki taraf se non-essential medicines ke liye deregulate prices ka faisla kia gaya hai. Bono regulatory tabdilon par sector ki profitability mein broad-based behtari ka intezar kia jarah he. AGP PKR100/sh ke target price ke saath top pick hai.
